查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1478594

类风湿性关节炎药物的市场规模 - 按药物类别、给药途径、销售管道和分销管道划分 - 区域前景、竞争策略和细分市场预测（截至 2033 年）

Rheumatoid Arthritis Drugs Market Size- By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 234 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计2033年，全球类风湿性关节炎治疗药物市场规模将成长至787,184.2亿日圆，复合年增长率为3.8%。

类风湿性关节炎是一种自体免疫疾病，人体的免疫系统会攻击自身组织，包括关节。用于治疗类风湿性关节炎的药物称为抗风湿药物。所有年龄层的人都受到这种疾病的影响，但老年人最容易受到这种疾病的影响。类风湿性关节炎的症状包括关节肿胀、僵硬、疼痛和不适。目前尚无治疗类风湿性关节炎的既定治疗方法。

2020 年 1 月 30 日，世界卫生组织 (WHO) 将 COVID-19 认定为全球突发公共卫生事件。 COVID-19 已影响全球约 210 个国家。根据《刺胳针风湿病学 2020》报导，类风湿性关节炎患者感染 COVID-19 可能会导致严重症状。某些 DMARD，例如羟氯喹，通常用于治疗类风湿性关节炎，但也正在研究作为潜在的 COVID-19 治疗。

本报告调查了全球类风湿性关节炎治疗药物市场，并提供了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测、各个细分市场/地区/主要国家的详细分析、竞争状况，我们编制了以下概况：主要企业。

目录

第一章简介

第二章调查方法

第三章执行摘要

第四章市场动态

  • 促进因素、抑制因素、机会与挑战分析
  • COVID-19 对市场的影响

第五章 市场变数与展望

  • SWOT分析
  • PESTEL分析
  • 波特五力分析
  • 热图分析

第六章 竞争状况

  • 製造地、销售区域、产品类型分布
  • 併购、联盟、产品发布、合作

第七章全球类类风湿性关节炎关节炎药物市场：依药物类别

  • 全球市场规模、份额和预测
  • 缓解疾病抗风湿药物 (DMARD)
  • 非类固醇消炎剂(NSAID)
  • 皮质类固醇
  • 降尿酸药
  • 其他的

第八章全球类类风湿性关节炎关节炎药物市场：途径分类

  • 全球市场规模、份额和预测
  • 口服
  • 胃肠外的

第九章全球类类风湿性关节炎药物市场：依销售管道划分

  • 全球市场规模、份额和预测
  • 处方药
  • 非处方药

第10章全球类类风湿性关节炎关节炎药物市场：依分销管道分类

  • 全球市场规模、份额和预测
  • 医院药房
  • 零售药房
  • 网路药房

第十一章全球类类风湿性关节炎关节炎药物市场预测

  • 市场规模/市场占有率

第十二章全球类风湿性关节炎药物市场：按地区

  • 市场规模/市场占有率趋势/预测
  • 亚太地区
  • 欧洲
  • 中东/非洲
  • 北美洲
  • 拉丁美洲

第十三章 公司简介

  • AbbVie Inc.
  • Johnson & Johnson Innovative Medicine
  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • 其他的

第14章简称

第十五章 参考链接

第16章结论

第十七章 研究范围

简介目录
Product Code: PHAR2406

Rheumatoid Arthritis Drugs Market Introduction and Overview

According to SPER market research, Rheumatoid Arthritis Drugs Market Size- By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033 state that the Global Rheumatoid Arthritis Drugs Market is predicted to reach 78718.42 million by 2033 with a CAGR of 3.8%.

Rheumatoid arthritis is an autoimmune disease that results in the body's immune system attacking its own tissues, including joints. This leads to edema and painful joint stiffness. A medication used to treat rheumatoid arthritis is known as an anti-rheumatic medication. All ages are affected by this ailment, albeit the elderly are most susceptible to it. Rheumatoid arthritis symptoms include swelling, stiffness, pain, and discomfort in the joints. Rheumatoid arthritis currently has no recognized treatment.

On January 30, 2020, the World Health Organization (WHO) deemed the COVID-19 pandemic a global public health emergency. Globally, COVID-19 has had an impact on around 210 countries. Patients with rheumatoid arthritis who also have COVID-19 infection may be more likely to experience severe symptoms and other problems, according to the Lancet Rheumatology 2020. Certain DMARDs, such hydroxychloroquine, are being studied as possible COVID-19 therapies in addition to being often used to treat rheumatoid arthritis.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered AbbVie Inc, Johnson & Johnson Innovative Medicine, Amgen Inc, Pfizer Inc, Novartis AG, Sanofi S.A, F. Hoffmann-La Roche Ltd, Merck & Co, Inc, Bristol-Myers Squibb Company, and Eli Lilly and Company.

Rheumatoid Arthritis Drugs Market Segmentation

By Drug Class Type: Based on the Drug Class Type, Global Rheumatoid Arthritis Drugs Market is segmented as, Disease-modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Others.

By Route of Administration: Based on the Route of Administration, Global Rheumatoid Arthritis Drugs Market is segmented as; Oral, Parenteral.

By Sales Channel: Based on the Sales Channel, Global Rheumatoid Arthritis Drugs Market is segmented as; Prescription-based Drugs, Over-the-counter Drugs.

By Distribution Channel: Based on the Distribution Channel, Global Rheumatoid Arthritis Drugs Market is segmented as; Hospital Pharmacy, Retail Pharmacy, Online Pharmacy.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impacts of the Global Rheumatoid Arthritis Drugs Market

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTER's Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Rheumatoid Arthritis Drugs Market Manufacturing Base Distribution, Sales Area, Ingredients
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Rheumatoid Arthritis Drugs Market

7. Global Rheumatoid Arthritis Drugs Market, By Drug Class Type (USD Million) 2020-2033

  • 7.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Drug Class Type, 2020-2026
  • 7.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Drug Class Type, 2027-2033
  • 7.3. Disease-modifying Anti-Rheumatic Drugs (DMARDs)
  • 7.4. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • 7.5. Corticosteroids
  • 7.6. Uric Acid Drugs
  • 7.7. Others

8. Global Rheumatoid Arthritis Drugs Market, By Route of Administration (USD Million) 2020-2033

  • 8.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Route of Administration, 2020-2026
  • 8.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Route of Administration, 2027-2033
  • 8.3. Oral
  • 8.4. Parenteral

9. Global Rheumatoid Arthritis Drugs Market, By Sales Channel (USD Million) 2020-2033

  • 9.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Sales Channel, 2020-2026
  • 9.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Sales Channel, 2027-2033
  • 9.3. Prescription-based Drugs
  • 9.4. Over-the-counter Drugs

10. Global Rheumatoid Arthritis Drugs Market, By Distribution Channel (USD Million) 2020-2033

  • 10.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Distribution Channel, 2020-2026
  • 10.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Distribution Channel, 2027-2033
  • 10.3. Hospital Pharmacy
  • 10.4. Retail Pharmacy
  • 10.5. Online Pharmacy

11. Global Rheumatoid Arthritis Drugs Market, Forecast, 2020-2033 (USD Million)

  • 11.1. Global Rheumatoid Arthritis Drugs Market Size and Market Share

12. Global Rheumatoid Arthritis Drugs Market, By Region, 2020-2033 (USD Million)

  • 12.1. Global Rheumatoid Arthritis Drugs Market Size and Market Share, By Region (2020-2026)
  • 12.2. Global Rheumatoid Arthritis Drugs Market Size and Market Share, By Region (2027-2033)
  • 12.3. Asia-Pacific
    • 12.3.1. Australia
    • 12.3.2. China
    • 12.3.3. India
    • 12.3.4. Japan
    • 12.3.5. South Korea
    • 12.3.6. Rest of Asia-Pacific
  • 12.4. Europe
    • 12.4.1. France
    • 12.4.2. Germany
    • 12.4.3. Italy
    • 12.4.4. Spain
    • 12.4.5. United Kingdom
    • 12.4.6. Rest of Europe
  • 12.5. Middle East and Africa
    • 12.5.1. Kingdom of Saudi Arabia
    • 12.5.2. United Arab Emirates
    • 12.5.3. Qatar
    • 12.5.4. South Africa
    • 12.5.5. Egypt
    • 12.5.6. Morocco
    • 12.5.7. Nigeria
    • 12.5.8. Rest of Middle-East and Africa
  • 12.6. North America
    • 12.6.1. Canada
    • 12.6.2. Mexico
    • 12.6.3. United States
  • 12.7. Latin America
    • 12.7.1. Argentina
    • 12.7.2. Brazil
    • 12.7.3. Rest of Latin America

13. Company Profile

  • 13.1. AbbVie Inc.
    • 13.1.1. Company details
    • 13.1.2. Financial outlook
    • 13.1.3. Product summary
    • 13.1.4. Recent developments
  • 13.2. Johnson & Johnson Innovative Medicine
    • 13.2.1. Company details
    • 13.2.2. Financial outlook
    • 13.2.3. Product summary
    • 13.2.4. Recent developments
  • 13.3. Amgen Inc.
    • 13.3.1. Company details
    • 13.3.2. Financial outlook
    • 13.3.3. Product summary
    • 13.3.4. Recent developments
  • 13.4. Pfizer Inc.
    • 13.4.1. Company details
    • 13.4.2. Financial outlook
    • 13.4.3. Product summary
    • 13.4.4. Recent developments
  • 13.5. Novartis AG
    • 13.5.1. Company details
    • 13.5.2. Financial outlook
    • 13.5.3. Product summary
    • 13.5.4. Recent developments
  • 13.6. Sanofi S.A.
    • 13.6.1. Company details
    • 13.6.2. Financial outlook
    • 13.6.3. Product summary
    • 13.6.4. Recent developments
  • 13.7. F. Hoffmann-La Roche Ltd.
    • 13.7.1. Company details
    • 13.7.2. Financial outlook
    • 13.7.3. Product summary
    • 13.7.4. Recent developments
  • 13.8. Merck & Co., Inc.
    • 13.8.1. Company details
    • 13.8.2. Financial outlook
    • 13.8.3. Product summary
    • 13.8.4. Recent developments
  • 13.9. Bristol-Myers Squibb Company
    • 13.9.1. Company details
    • 13.9.2. Financial outlook
    • 13.9.3. Product summary
    • 13.9.4. Recent developments
  • 13.10. Eli Lilly and Company
    • 13.10.1. Company details
    • 13.10.2. Financial outlook
    • 13.10.3. Product summary
    • 13.10.4. Recent developments
  • 13.11. Others

14. List of Abbreviations

15. Reference Links

16. Conclusion

17. Research Scope